Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study

P. N. Tariot, R. Erb, A. Leibovici, C. A. Podgorski, Christopher Cox, J. Asnis, J. Kolassa, C. Irvine

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To determine the effects of carbamazepine versus placebo on ratings of behavior in agitated nursing home patients with dementia. DESIGN: Nonrandomized, placebo-controlled, crossover trial conducted in 25 patients in two nursing homes. INTERVENTION: Carbamazepine and placebo were administered during two 5-week periods separated by a 2-week washout. The carbamazepine dose was determined for each patient by a nonblinded physician who did not participate in ratings (modal dose 300 mg/day). MEASUREMENTS: The primary outcome measures were Brief Psychiatric Rating Scale scores and Clinical Global Impression of Change, rated by blind observers. Secondary measures of behavior, adversity, cognition, and functional status were also included. MAIN RESULTS: Median total Brief Psychiatric Rating Scale score decreased 7 points on carbamazepine versus 3 on placebo (P = 0.03). Sixteen subjects were rated as improved globally on carbamazepine versus four on placebo (P = 0.001). Secondary measures of behavior showed similar changes at significant or suggestive (P <0.10) levels. One subject developed carbamazepine-induced tics, and one died with a pneumonia. There was minimal other adversity. CONCLUSION: This preliminary study suggests that carbamazepine in low doses can reduce agitated behaviors in some patients, with limited adversity resulting. Further research is required to confirm and extend this finding before it can be considered routine clinical practice.

Original languageEnglish (US)
Pages (from-to)1160-1166
Number of pages7
JournalJournal of the American Geriatrics Society
Volume42
Issue number11
StatePublished - 1994
Externally publishedYes

Fingerprint

Carbamazepine
Nursing Homes
Dementia
Placebos
Brief Psychiatric Rating Scale
Therapeutics
Tics
Cross-Over Studies
Cognition
Pneumonia
Outcome Assessment (Health Care)
Physicians
Research

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Tariot, P. N., Erb, R., Leibovici, A., Podgorski, C. A., Cox, C., Asnis, J., ... Irvine, C. (1994). Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study. Journal of the American Geriatrics Society, 42(11), 1160-1166.

Carbamazepine treatment of agitation in nursing home patients with dementia : A preliminary study. / Tariot, P. N.; Erb, R.; Leibovici, A.; Podgorski, C. A.; Cox, Christopher; Asnis, J.; Kolassa, J.; Irvine, C.

In: Journal of the American Geriatrics Society, Vol. 42, No. 11, 1994, p. 1160-1166.

Research output: Contribution to journalArticle

Tariot, PN, Erb, R, Leibovici, A, Podgorski, CA, Cox, C, Asnis, J, Kolassa, J & Irvine, C 1994, 'Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study', Journal of the American Geriatrics Society, vol. 42, no. 11, pp. 1160-1166.
Tariot, P. N. ; Erb, R. ; Leibovici, A. ; Podgorski, C. A. ; Cox, Christopher ; Asnis, J. ; Kolassa, J. ; Irvine, C. / Carbamazepine treatment of agitation in nursing home patients with dementia : A preliminary study. In: Journal of the American Geriatrics Society. 1994 ; Vol. 42, No. 11. pp. 1160-1166.
@article{c5d8ad7ecd21400495d63063314719ed,
title = "Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study",
abstract = "OBJECTIVE: To determine the effects of carbamazepine versus placebo on ratings of behavior in agitated nursing home patients with dementia. DESIGN: Nonrandomized, placebo-controlled, crossover trial conducted in 25 patients in two nursing homes. INTERVENTION: Carbamazepine and placebo were administered during two 5-week periods separated by a 2-week washout. The carbamazepine dose was determined for each patient by a nonblinded physician who did not participate in ratings (modal dose 300 mg/day). MEASUREMENTS: The primary outcome measures were Brief Psychiatric Rating Scale scores and Clinical Global Impression of Change, rated by blind observers. Secondary measures of behavior, adversity, cognition, and functional status were also included. MAIN RESULTS: Median total Brief Psychiatric Rating Scale score decreased 7 points on carbamazepine versus 3 on placebo (P = 0.03). Sixteen subjects were rated as improved globally on carbamazepine versus four on placebo (P = 0.001). Secondary measures of behavior showed similar changes at significant or suggestive (P <0.10) levels. One subject developed carbamazepine-induced tics, and one died with a pneumonia. There was minimal other adversity. CONCLUSION: This preliminary study suggests that carbamazepine in low doses can reduce agitated behaviors in some patients, with limited adversity resulting. Further research is required to confirm and extend this finding before it can be considered routine clinical practice.",
author = "Tariot, {P. N.} and R. Erb and A. Leibovici and Podgorski, {C. A.} and Christopher Cox and J. Asnis and J. Kolassa and C. Irvine",
year = "1994",
language = "English (US)",
volume = "42",
pages = "1160--1166",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Carbamazepine treatment of agitation in nursing home patients with dementia

T2 - A preliminary study

AU - Tariot, P. N.

AU - Erb, R.

AU - Leibovici, A.

AU - Podgorski, C. A.

AU - Cox, Christopher

AU - Asnis, J.

AU - Kolassa, J.

AU - Irvine, C.

PY - 1994

Y1 - 1994

N2 - OBJECTIVE: To determine the effects of carbamazepine versus placebo on ratings of behavior in agitated nursing home patients with dementia. DESIGN: Nonrandomized, placebo-controlled, crossover trial conducted in 25 patients in two nursing homes. INTERVENTION: Carbamazepine and placebo were administered during two 5-week periods separated by a 2-week washout. The carbamazepine dose was determined for each patient by a nonblinded physician who did not participate in ratings (modal dose 300 mg/day). MEASUREMENTS: The primary outcome measures were Brief Psychiatric Rating Scale scores and Clinical Global Impression of Change, rated by blind observers. Secondary measures of behavior, adversity, cognition, and functional status were also included. MAIN RESULTS: Median total Brief Psychiatric Rating Scale score decreased 7 points on carbamazepine versus 3 on placebo (P = 0.03). Sixteen subjects were rated as improved globally on carbamazepine versus four on placebo (P = 0.001). Secondary measures of behavior showed similar changes at significant or suggestive (P <0.10) levels. One subject developed carbamazepine-induced tics, and one died with a pneumonia. There was minimal other adversity. CONCLUSION: This preliminary study suggests that carbamazepine in low doses can reduce agitated behaviors in some patients, with limited adversity resulting. Further research is required to confirm and extend this finding before it can be considered routine clinical practice.

AB - OBJECTIVE: To determine the effects of carbamazepine versus placebo on ratings of behavior in agitated nursing home patients with dementia. DESIGN: Nonrandomized, placebo-controlled, crossover trial conducted in 25 patients in two nursing homes. INTERVENTION: Carbamazepine and placebo were administered during two 5-week periods separated by a 2-week washout. The carbamazepine dose was determined for each patient by a nonblinded physician who did not participate in ratings (modal dose 300 mg/day). MEASUREMENTS: The primary outcome measures were Brief Psychiatric Rating Scale scores and Clinical Global Impression of Change, rated by blind observers. Secondary measures of behavior, adversity, cognition, and functional status were also included. MAIN RESULTS: Median total Brief Psychiatric Rating Scale score decreased 7 points on carbamazepine versus 3 on placebo (P = 0.03). Sixteen subjects were rated as improved globally on carbamazepine versus four on placebo (P = 0.001). Secondary measures of behavior showed similar changes at significant or suggestive (P <0.10) levels. One subject developed carbamazepine-induced tics, and one died with a pneumonia. There was minimal other adversity. CONCLUSION: This preliminary study suggests that carbamazepine in low doses can reduce agitated behaviors in some patients, with limited adversity resulting. Further research is required to confirm and extend this finding before it can be considered routine clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0028072872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028072872&partnerID=8YFLogxK

M3 - Article

C2 - 7963202

AN - SCOPUS:0028072872

VL - 42

SP - 1160

EP - 1166

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 11

ER -